Bristol Myers and Novartis halt trials of therapies for autoimmune diseases after detecting serious safety issues
Bristol Myers Squibb and Novartis halted clinical trials for CAR-T therapies targeting autoimmune diseases due to safety concerns. Bristol Myers paused a zola-cel study after detecting ICANS cases, while Novartis suspended rap-cel trials following three patient deaths. Both companies are investigating the issues, with Bristol Myers reporting non-fatal effects and Novartis analyzing data. The trials aimed to treat diseases like lupus and rheumatoid arthritis, with initial results showing promise.
How this was made
The 30-second read
Why it matters
Both companies face immediate reputational and financial risk, with possible stock declines.
Market read
Safety setbacks in high‑profile immunotherapy trials could trigger sector‑wide risk reassessment.
What to watch
Potential for accelerated regulatory scrutiny on CAR‑T platforms may affect future pipeline timelines.
Background
The article reports the first public disclosure of trial suspensions for two major pharma companies.
Ticker impact
Bristol Myers Squibb halted multiple CAR‑T autoimmune trials after detecting serious neurotoxicity (ICANS).
short‑term downside pressure
First‑report of safety‑related halt in a high‑profile immunotherapy program.
Novartis suspended several CAR‑T autoimmune trials after three patient deaths were reported.
short‑term downside pressure
First‑report of fatal outcomes in Novartis' experimental therapy.
Market effects
Biotech sector may see broader risk aversion toward CAR‑T and autoimmune programs.
U.S. biotech stocks could experience heightened volatility.
International investors in pharma may reassess exposure to experimental immunotherapies.
Counterpoint
If safety issues are isolated, the pause could be a short‑term overreaction, presenting a buying opportunity.
Key entities
- CompanyBristol Myers Squibb
US‑listed biopharma halting CAR‑T trials.
- CompanyNovartis
Swiss‑based pharma pausing CAR‑T trials after patient deaths.
